Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Utilizing the Crosstalk Among Aerosolized Phenformin, Methylene Blue, Photodynamic Therapy , Zinc and Potassium for Treating Severe COVID-19 Infection and Its Inflammatory Complication

NCT05003492 is registered in ClinicalTrials.gov with Amr kamel khalil Ahmed as lead sponsor.

NCT NCT05003492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05003492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Utilizing the Crosstalk Among Aerosolized Phenformin, Methylene Blue, Photodynamic Therapy , Zinc and Potassium for Treating Severe COVID-19 Infection and Its Inflammatory Complication
Lead sponsor
Amr kamel khalil Ahmed
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 30, 2021
Completion date
November 30, 2021
Enrollment
2 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19